Latest News
Generational Equity Advises LGM Pharma in Sale to New Harbor Capital
Wednesday 06 December 2017

6 December 2017 - US-based mergers and acquisitions advisor Generational Equity advised its client, US-based API company LGM Pharma, in its majority sale to US-based private equity firm New Harbor Capital LLC the firm said.

LGM specialises in streamlining the API supply chain throughout all development stages while providing complete technical capabilities and expert regulatory support for a range of products.

The company serves many active customers across biotech, generic pharma, contract manufacturing, specialty pharma, CDMOs, academic institutes, compounding and pharmaceutical manufacturing industries, supporting all stages of drug development and commercialization by supplying a wide range of APIs and by providing other value-added services.

Generational Equity Managing director Julie Sandoval's team, led by trusted affiliate Mike LoContewith support from Generational Equity VP Rebecca Gruman, successfully closed the deal.

LGM Pharma is an API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. LGM specialises in providing integrated sourcing options, complete technical capabilities and regulatory documentation support for a wide range of APIs.

New Harbor Capital is a Chicago-based private equity firm with over USD400 m of capital under management, focused on investing in lower middle market, growth-oriented healthcare, education and business services companies.

Generational Equity, DealForce, and Generational Capital Markets, member FINRA/SIPC, are part of the Generational Group, which is headquartered in Dallas and is an M and A advisory firm in North America.
Date Published: 06/12/2017
Target: LGM Pharma/majority stake
Country: USA
Sector: Pharmaceuticals
Type: LBO
Status: Closed
Buyer: New Harbor Capital
Terms of the deal were not disclosed